NeoGenomics, Inc. (NASDAQ:NEO) is on recovery track with 101.45% gain from a 1-year low price of $11.05. The company lost -4.95% to attain the price of $22.26 on 6/11/2019. Throughout the recent session, the prices were hovering between $22.05 and $23.5. These shares are 8.4% off its target price of $24.13 and the current market capitalization stands at $2.21B. The recent change has given its price a 2.84% lead over SMA 50 and -8.4% deficit over its 52-week high. The stock witnessed -2.75% declines, 14.51% gains and 56.87% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found NEO’s volatility during a week at 4.12% and during a month it has been found around 3.74%.

NeoGenomics, Inc. (NEO) Top Holders

Institutional investors currently hold around $1.88 billion or 78.8% in NEO stock. Look at its top three institutional owners: Blackrock Inc. owns $323.78 million in NeoGenomics, Inc., which represents roughly 14.65% of the company’s market cap and approximately 17.19% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 5,772,487 shares of the stock are valued at $135.19 million. The third largest holder is Janus Henderson Group Plc, which currently holds $119.45 million worth of this stock and that ownership represents nearly 5.4% of its market capitalization.

NeoGenomics, Inc. 13F Filings

At the end of March reporting period, 144 institutional holders increased their position in NeoGenomics, Inc. (NASDAQ:NEO) by some 20,253,609 shares, 115 decreased positions by 12,978,715 and 17 held positions by 47,225,685. That puts total institutional holdings at 80,458,009 shares, according to SEC filings. The stock grabbed 69 new institutional investments totaling 2,393,252 shares while 42 institutional investors sold out their entire positions totaling 5,447,392 shares.

NeoGenomics, Inc. (NASDAQ:NEO) Insider Trades

Multiple company employees have indulged in significant insider trading. NeoGenomics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director HIPP RAYMOND R has sold 150,000 shares of NeoGenomics, Inc. (NEO) in the trading session dated May. 08, 2019. These shares are worth $3,361,500 and were traded at $22.41 each. The SEC filing shows that Bonello William performed a sale of 7,200 shares. The Chief Strategy Officer disposed these shares by way of transaction on May. 06, 2019. The company’s shares were given away at $23.53 per share worth to an income of some $169,416 to the account of Bonello William.

President, Pharma Services, CARDOZA GEORGE, sold 151,676 common shares of NeoGenomics, Inc. (NEO) in the open market. In a transaction dated May. 03, 2019, the shares were put up for sale at an average price of $22.82, raking in a sum of $3,461,246. After this sale, 320,831 common shares of NEO are directly owned by the insider, with total stake valued at $7,141,698.

In the transaction dated May. 03, 2019, a great number of shares sold came courtesy the VP and Chief Culture Officer; BALLIET JENNIFER disposed a total of 30,000 shares at an average price of $22.74, amounting to approximately $682,200. The insider now directly owns 22,862 shares worth $508,908.

NeoGenomics, Inc. (NEO) Analyst Guide

Several analysts have released their opinion on NeoGenomics, Inc. (NASDAQ:NEO), with 5 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 4 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.44 average brokerage recommendation [T1].